EyePoint Pharmaceuticals, Inc. — Director's Dealing 2019

Jun 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-06-25

Reporting Person: ROGERS MICHAEL W (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-25	Stock Option (Right to Buy)	$2.65	A	40000.00	Acquired	2020-06-25	Common Stock (40000.00)	Direct

Footnotes

F1: Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the "Committee") of EyePoint Pharmaceuticals, Inc. (the "Registrant"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the "Plan Amendment").

F2: The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019.

F3: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020